domingo, 13 de septiembre de 2026
The gifts from pharma companies that keep on giving Study finds doctors continue to embrace industry freebies over time, despite rancorous debate over the issue
https://www.statnews.com/pharmalot/2026/09/10/many-doctors-still-embrace-pharma-freebies-rely-on-sales-reps/
By Ed SilvermanSept. 10, 2026
Pharmalot Columnist, Senior Writer
Why two promising heart drugs flopped and what’s next By Adam Feuerstein, Elaine Chen, and Allison DeAngelisSept. 10, 2026
https://www.statnews.com/2026/09/10/readout-loud-podcast-heart-disease-drugs-failed-trials/
By Adam Feuerstein, Elaine Chen, and Allison DeAngelisSept. 10, 2026
Platinum-based chemotherapy in childhood causes mutations that age the liver Study shows need for lifelong monitoring for potential cancers, authors say
https://www.statnews.com/2026/09/10/childhood-chemotherapy-cisplatin-carboplatin-new-study-liver-impact/
By Annalisa MerelliSept. 10, 2026
Contributing Writer
An AI tool aims to catch harder-to-detect heart attacks in EKGs FDA authorizes Powerful Medical’s Queen of Hearts algorithm to help triage heart attacks
https://www.statnews.com/2026/09/11/fda-new-ekg-heart-attack-detection-algo-queen-of-hearts/
By Katie PalmerSept. 11, 2026
Health Tech Correspondent
Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field Expert says that after resurgence in cardiovascular trials, investments will be harder to come by
https://www.statnews.com/2026/09/11/novartis-novo-nordisk-cardiovascular-drug-trials-fallout/
By Allison DeAngelis and Adam FeuersteinSept. 11, 2026
Adam Feuerstein
adam.feuerstein@statnews.com
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
Suscribirse a:
Entradas (Atom)
